相关实验视频
Updated: Jul 20, 2025

08:05
Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
18.4K
结合的低性成本使得全性ERK2抑制剂具有高选择性
Hajime Sugiyama1, Mayu Yoshida2, Haruna Nagao3
1Mitsubishi Chemical Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-8502, Japan.
Bioorganic & medicinal chemistry letters
|August 6, 2023
概括
研究人员开发了一种强效和选择性的细胞外信号调节激酶2 (ERK2) 抑制剂. 计算研究揭示了它对ERK2的高选择性超过p38α MAPK,证明了新的癌症和糖尿病治疗的潜力.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 细胞外信号调节激酶2 (ERK2),一种基激活蛋白激酶 (MAPK),对细胞过程至关重要.
- ERK2是癌症和2型糖尿病的重要药物标.
- 之前的in silico查发现了一种ERK2抑制剂 (化合物1),向一个全位.
研究的目的:
- 评估化合物1的选择性和结合方式 1.
- 阐明化合物1的强度和选择性的结构基础.
- 为了证明开发选择性ERK2抑制剂的可行性.
主要方法:
- 在体外测试以评估对p38α MAPK的选择性.
- 进行X射线结晶学以确定化合物1与ERK2.2的结合结构.
- 碎片分子轨道 (FMO) 计算以分析结合相互作用.
- 计算研究,以调查对结合的性贡献.
主要成果:
- 化合物1对ERK2对p38αMAPK具有很高的选择性.
- 结晶结构确认的化合物1与ERK2.2的全位结合.
- FMO的计算提供了改善衍生品效力的见解.
- 结合的低性成本被确定为ERK2选择性的关键.
结论:
- 化合物1是一种强效和选择性的ERK2抑制剂.
- 该研究为设计改进的ERK2抑制剂提供了结构和计算基础.
- 这些发现支持开发针对ERK2的新疗法,用于癌症和糖尿病.
相关概念视频
Allosteric Regulation
58.2K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.2K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
The Equilibrium Binding Constant and Binding Strength
13.0K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.0K
Drug-Receptor Bonds
2.9K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.9K

